(Reuters) -The U.S. Food and Drug Administration said on Friday that supply interruptions of hemodialysis bloodlines, a key component in dialysis devices, are expected to continue through early fall 2025 due to recent supplier issues.
Hemodialysis bloodlines are sets of tubes that connect a patient’s bloodstream to the dialysis device during treatment.
The health agency’s statement follows a January announcement from medical device maker B. Braun, which cited supply and labor constraints disrupting production of some hemodialysis bloodlines, with inventory expected to run out by January 20.
The FDA recommended health care providers conserve the use of the bloodlines when possible, adding that it is monitoring the situation and is working with manufacturers and dialysis providers to mitigate impact on patients.
(Reporting by Sneha S K in Bengaluru; Editing by Tasim Zahid)
